Novel therapeutic targets for pancreatic cancer

World Journal of Gastroenterology

Volumn 20, Issue 31, 2014, Pages 10825-10844

  Tang, Shing Chun ^a   Chen, Yang Chao ^a,b  

^a Prince of Wales Hospital   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

BMI1; CTHRC1; DR5; EZH2; HDAC; HER3; Hypoxic condition; IAP; NDRG1; Nodal Activin signaling; Non coding; Notch signaling; Pancreatic cancer; Pancreatic cancer stem cell; PAR2; RAC1; RalGEFRAl; RNA; Tumour microenvironment

Indexed keywords

ACTIVIN; BMI1 PROTEIN; CELL SURFACE MARKER; CELL SURFACE PROTEIN; COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HISTONE DEACETYLASE; HOX TRANSCRIPT ANTISENSE RNA; HYALURONIC ACID; INHIBITOR OF APOPTOSIS PROTEIN; K RAS PROTEIN; LONG UNTRANSLATED RNA; MATRIX METALLOPROTEINASE; METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1; MICRORNA; MICRORNA 143; MICRORNA 200; MICRORNA 34; N MYC DOWNSTREAM REGULATED GENE 1 PROTEIN; NODAL SIGNALING PROTEIN; PROTEINASE ACTIVATED RECEPTOR 2; RAC1 PROTEIN; RAS LIKE GUANINE NUCLEOTIDE EXCHANGE FACTOR; SECRETORY PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSMEMBRANE PROTEASE SERINE 4; UNCLASSIFIED DRUG; UNTRANSLATED RNA; UVOMORULIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER CELL; CANCER GROWTH; CANCER STEM CELL; CELL PROLIFERATION; ENERGY METABOLISM; HUMAN; PANCREAS CANCER; PANCREATIC STELLATE CELL; REVIEW; STEM CELL; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; RNA, UNTRANSLATED; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84909630685     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i31.10825     Document Type: Review

References (184)

1. Sarkar FH, Banerjee S, Li Y. Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol Appl Pharmacol 2007; 224: 326-336 [PMID: 17174370 DOI: 10.1016/j.taap.2006.11.007]
2. Silvestris N, Gnoni A, Brunetti AE, Vincenti L, Santini D, Tonini G, Merchionne F, Maiello E, Lorusso V, Nardulli P, Azzariti A, Reni M. Target therapies in pancreatic carcinoma. Curr Med Chem 2014; 21: 948-965 [PMID: 23992319]
3. Iovanna J, Mallmann MC, Gonc¸alves A, Turrini O, Dagorn JC. Current knowledge on pancreatic cancer. Front Oncol 2012; 2: 6 [PMID: 22655256 DOI: 10.3389/fonc.2012.00006]
4. Hill R, Rabb M, Madureira PA, Clements D, Gujar SA, Waisman DM, Giacomantonio CA, Lee PW. Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. Cell Death Dis 2013; 4: e791 [PMID: 24008735 DOI: 10.1038/cddis.2013.307]
5. Algül H, Treiber M, Lesina M, Schmid RM. Mechanisms of disease: chronic inflammation and cancer in the pancreas - a potential role for pancreatic stellate cells? Nat Clin Pract Gastroenterol Hepatol 2007; 4: 454-462 [PMID: 17667994 DOI: 10.1038/ncpgasthep0881]
6. Cowley MJ, Chang DK, Pajic M, Johns AL, Waddell N, Grimmond SM, Biankin AV. Understanding pancreatic cancer genomes. J Hepatobiliary Pancreat Sci 2013; Epub ahead of print [PMID: 23660961 DOI: 10.1007/s00534-013-0610-6]
7. Danovi SA, Wong HH, Lemoine NR. Targeted therapies for pancreatic cancer. Br Med Bull 2008; 87: 97-130 [PMID: 18753179 DOI: 10.1093/bmb/ldn027]
8. Tang L, Dai DL, Su M, Martinka M, Li G, Zhou Y. Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res 2006; 12: 3716-3722 [PMID: 16778098 DOI: 10.1158/1078-0432.CCR-06-0030]
9. Pyagay P, Heroult M, Wang Q, Lehnert W, Belden J, Liaw L, Friesel RE, Lindner V. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 2005; 96: 261-268 [PMID: 15618538]
10. Park EH, Kim S, Jo JY, Kim SJ, Hwang Y, Kim JM, Song SY, Lee DK, Koh SS. Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. Carcinogenesis 2013; 34: 694-702 [PMID: 23222813 DOI: 10.1093/carcin/bgs378]
11. Wang Y. Wnt/Planar cell polarity signaling: a new paradigm for cancer therapy. Mol Cancer Ther 2009; 8: 2103-2109 [PMID: 19671746 DOI: 10.1158/1535-7163.MCT-09-0282]
12. Avizienyte E, Frame MC. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 2005; 17: 542-547 [PMID: 16099634 DOI: 10.1016/j.ceb.2005.08.007]
13. Didsbury J, Weber RF, Bokoch GM, Evans T, Snyderman R. rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem 1989; 264: 16378-16382 [PMID: 2674130]
14. Heid I, Lubeseder-Martellato C, Sipos B, Mazur PK, Lesina M, Schmid RM, Siveke JT. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology 2011; 141: 719-730, 730.e1-7 [PMID: 21684285 DOI: 10.1053/j.gastro.2011.04.043]
15. Razidlo GL, Wang Y, Chen J, Krueger EW, Billadeau DD, McNiven MA. Dynamin 2 potentiates invasive migration of pancreatic tumor cells through stabilization of the Rac1 GEF Vav1. Dev Cell 2013; 24: 573-585 [PMID: 23537630 DOI: 10.1016/j.devcel.2013.02.010]
16. Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng Z, Liu L. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene 2014; 33: 514-524 [PMID: 23334332 DOI: 10.1038/onc.2012.598]
17. Guo X, Wang M, Jiang J, Xie C, Peng F, Li X, Tian R, Qin R. Balanced Tiam1-rac1 and RhoA drives proliferation and invasion of pancreatic cancer cells. Mol Cancer Res 2013; 11: 230-239 [PMID: 23322732 DOI: 10.1158/1541-7786.MCR-12-0632]
18. Lazer G, Katzav S. Guanine nucleotide exchange factors for RhoGTPases: good therapeutic targets for cancer therapy? Cell Signal 2011; 23: 969-979 [PMID: 21044680 DOI: 10.1016/j.cellsig.2010.10.022]
19. Neel NF, Martin TD, Stratford JK, Zand TP, Reiner DJ, Der CJ. The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. Genes Cancer 2011; 2: 275-287 [PMID: 21779498 DOI: 10.1177/1947601911407329]
20. Kashatus DF. Ral GTPases in tumorigenesis: emerging from the shadows. Exp Cell Res 2013; 319: 2337-2342 [PMID: 23830877 DOI: 10.1016/j.yexcr.2013.06.020]
21. Lim KH, O'Hayer K, Adam SJ, Kendall SD, Campbell PM, Der CJ, Counter CM. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol 2006; 16: 2385-2394 [PMID: 17174914 DOI: 10.1016/j.cub.2006.10.023]
22. Neyraud V, Aushev VN, Hatzoglou A, Meunier B, Cascone I, Camonis J. RalA and RalB proteins are ubiquitinated GT-Pases, and ubiquitinated RalA increases lipid raft exposure at the plasma membrane. J Biol Chem 2012; 287: 29397-29405 [PMID: 22700969 DOI: 10.1074/jbc.M112.357764]
23. Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, Counter CM. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005; 7: 533-545 [PMID: 15950903 DOI: 10.1016/j.ccr.2005.04.030]
24. Chien Y, White MA. RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival. EMBO Rep 2003; 4: 800-806 [PMID: 12856001 DOI: 10.1038/sj.embor.embor899]
25. Balasubramanian N, Meier JA, Scott DW, Norambuena A, White MA, Schwartz MA. RalA-exocyst complex regulates integrin-dependent membrane raft exocytosis and growth signaling. Curr Biol 2010; 20: 75-79 [PMID: 20005108 DOI: 10.1016/j.cub.2009.11.016]
26. Avila JL, Kissil JL. Notch signaling in pancreatic cancer: oncogene or tumor suppressor? Trends Mol Med 2013; 19: 320-327 [PMID: 23545339 DOI: 10.1016/j.molmed.2013.03.003]
27. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, Sarkar FH. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 2010; 1806: 258-267 [PMID: 20600632 DOI: 10.1016/j.bbcan.2010.06.001]
28. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, Sriuranpong V, Iso T, Meszoely IM, Wolfe MS, Hruban RH, Ball DW, Schmid RM, Leach SD. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003; 3: 565-576 [PMID: 12842085 DOI: 10.1016/S1535-6108(03)00140-5]
29. Hanlon L, Avila JL, Demarest RM, Troutman S, Allen M, Ratti F, Rustgi AK, Stanger BZ, Radtke F, Adsay V, Long F, Capobianco AJ, Kissil JL. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res 2010; 70: 4280-4286 [PMID: 20484026 DOI: 10.1158/0008-5472.CAN-09-4645]
30. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, Rudolf M, Siziopikou K, Kast WM, Miele L. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Rastransformed cells. Nat Med 2002; 8: 979-986 [PMID: 12185362 DOI: 10.1038/nm754]
31. Gurdon JB, Bourillot PY. Morphogen gradient interpretation. Nature 2001; 413: 797-803 [PMID: 11677596 DOI: 10.1038/35101500]
32. Gurdon JB, Harger P, Mitchell A, Lemaire P. Activin signalling and response to a morphogen gradient. Nature 1994; 371: 487-492 [PMID: 7935761 DOI: 10.1038/371487a0]
33. Lee KL, Lim SK, Orlov YL, Yit le Y, Yang H, Ang LT, Poellinger L, Lim B. Graded Nodal/Activin signaling titrates conversion of quantitative phospho-Smad2 levels into qualitative embryonic stem cell fate decisions. PLoS Genet 2011; 7: e1002130 [PMID: 21731500 DOI: 10.1371/journal.pgen.1002130]
34. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcala S, Rodriguez-Arabaolaza I, Ramirez JC, Torres-Ruíz R, Garcia E, Hidalgo M, Cebrián DÁ, Heuchel R, Löhr M, Berger F, Bartenstein P, Aicher A, Heeschen C. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011; 9: 433-446 [PMID: 22056140 DOI: 10.1016/j.stem.2011.10.001]
35. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461 [PMID: 19460966 DOI: 10.1126/science.1171362]
36. Sun J, Zhang D, Bae DH, Sahni S, Jansson P, Zheng Y, Zhao Q, Yue F, Zheng M, Kovacevic Z, Richardson DR. Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis 2013; 34: 1943-1954 [PMID: 23671130 DOI: 10.1093/carcin/bgt163]
37. Lv XH, Chen JW, Zhao G, Feng ZZ, Yang DH, Sun WW, Fan JS, Zhu GH. N-myc downstream-regulated gene 1/Cap43 may function as tumor suppressor in endometrial cancer. J Cancer Res Clin Oncol 2012; 138: 1703-1715 [PMID: 22678098 DOI: 10.1007/s00432-012-1249-4]
38. Angst E, Sibold S, Tiffon C, Weimann R, Gloor B, Candinas D, Stroka D. Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer. Br J Cancer 2006; 95: 307-313 [PMID: 16832411 DOI: 10.1038/sj.bjc.6603256]
39. Angst E, Dawson DW, Nguyen A, Park J, Go VL, Reber HA, Hines OJ, Eibl G. Epigenetic regulation affects N-myc down-stream-regulated gene 1 expression indirectly in pancreatic cancer cells. Pancreas 2010; 39: 675-679 [PMID: 20173668 DOI: 10.1097/MPA.0b013e3181c8b476]
40. Kovacevic Z, Chikhani S, Lui GY, Sivagurunathan S, Richardson DR. The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid Redox Signal 2013; 18: 874-887 [PMID: 22462691 DOI: 10.1089/ars.2011.4273]
41. Bao B, Ali S, Ahmad A, Azmi AS, Li Y, Banerjee S, Kong D, Sethi S, Aboukameel A, Padhye SB, Sarkar FH. Hypoxiainduced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One 2012; 7: e50165 [PMID: 23272057 DOI: 10.1371/journal.pone.0050165]
42. Guillaumond F, Leca J, Olivares O, Lavaut MN, Vidal N, Berthezène P, Dusetti NJ, Loncle C, Calvo E, Turrini O, Iovanna JL, Tomasini R, Vasseur S. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci USA 2013; 110: 3919-3924 [PMID: 23407165 DOI: 10.1073/pnas.1219555110]
43. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, Zimmerman LJ, Liebler DC, Slebos RJ, Lorkiewicz PK, Higashi RM, Fan TW, Dang CV. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012; 15: 110-121 [PMID: 22225880 DOI: 10.1016/j.cmet.2011.12.009]
44. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012; 149: 656-670 [PMID: 22541435 DOI: 10.1016/j.cell.2012.01.058]
45. Dando I, Donadelli M, Costanzo C, Dalla Pozza E, D'Alessandro A, Zolla L, Palmieri M. Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells. Cell Death Dis 2013; 4: e664 [PMID: 23764845 DOI: 10.1038/cddis.2013.151]
46. Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, Stampfer MJ, Sato K, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, McTiernan A, Phillips LS, Cochrane BB, Pollak MN, Manson JE, Giovannucci EL, Fuchs CS. Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. J Natl Cancer Inst 2013; 105: 1027-1035 [PMID: 23847240 DOI: 10.1093/jnci/djt123]
47. Donadelli M, Dando I, Zaniboni T, Costanzo C, Dalla Pozza E, Scupoli MT, Scarpa A, Zappavigna S, Marra M, Abbruzzese A, Bifulco M, Caraglia M, Palmieri M. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis 2011; 2: e152 [PMID: 21525939 DOI: 10.1038/cddis.2011.36]
48. Murray J, Taylor SW, Zhang B, Ghosh SS, Capaldi RA. Oxidative damage to mitochondrial complex I due to peroxynitrite: identification of reactive tyrosines by mass spectrometry. J Biol Chem 2003; 278: 37223-37230 [PMID: 12857734 DOI: 10.1074/jbc.M305694200]
49. Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, Hidalgo M. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 2010; 9: 2582-2592 [PMID: 20660600 DOI: 10.1158/1535-7163.MCT-10-0370]
50. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004; 16: 139-144 [PMID: 14636884 DOI: 10.1016/j.cellsig.2003.08.007]
51. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611-620 [PMID: 10894161 DOI: 10.1016/S1074-7613(00)80212-5]
52. Kong R, Jia G, Cheng ZX, Wang YW, Mu M, Wang SJ, Pan SH, Gao Y, Jiang HC, Dong DL, Sun B. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. PLoS One 2012; 7: e37222 [PMID: 22666346 DOI: 10.1371/journal.pone.0037222]
53. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002; 2: 420-430 [PMID: 12189384 DOI: 10.1038/nrc821]
54. Chang LH, Pan SL, Lai CY, Tsai AC, Teng CM. Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-α expression and MEK/VEGF-Amediated angiogenesis. Am J Pathol 2013; 183: 566-575 [PMID: 23764046 DOI: 10.1016/j.ajpath.2013.04.022]
55. Dutra-Oliveira A, Monteiro RQ, Mariano-Oliveira A. Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines. Biochem Biophys Res Commun 2012; 421: 221-227 [PMID: 22497886 DOI: 10.1016/j.bbrc.2012.03.140]
56. Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K, Wheeler J, Gleave M, Sanghera J, Dedhar S. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 2004; 5: 79-90 [PMID: 14749128 DOI: 10.1016/S1535-6108(03)00281-2]
57. Shi K, Queiroz KC, Stap J, Richel DJ, Spek CA. Protease-activated receptor-2 induces migration of pancreatic cancer cells in an extracellular ATP-dependent manner. J Thromb Haemost 2013; 11: 1892-1902 [PMID: 23899344 DOI: 10.1111/jth.12361]
58. Desai MD, Saroya BS, Lockhart AC. Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. Expert Opin Investig Drugs 2013; 22: 341-356 [PMID: 23316969 DOI: 10.1517/13543784.2013.761972]
59. Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnière M, Vié N, Robert B, Monnet C, Bouayadi K, Kharrat H, Mondon P, Pèlegrin A, Chardès T. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia 2013; 15: 335-347 [PMID: 23479511 DOI: 10.1593/neo.121960]
60. Hirakawa T, Nakata B, Amano R, Kimura K, Shimizu S, Ohira G, Yamada N, Ohira M, Hirakawa K. HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. Oncology 2011; 81: 192-198 [PMID: 22067729 DOI: 10.1159/000333825]
61. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007; 97: 453-457 [PMID: 17667926 DOI: 10.1038/sj.bjc.6603910]
62. Berlin J, Keedy VL, Janne PA, Yee L, Rizvi NA, Jin X, Copigneaux C, Hettmann T, Beaupre DM, LoRusso P. A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors. 2011 ASCO Annual Meeting. Available from: URL: http://meetinglibrary.asco.org/content/84026-102
63. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010; 70: 2485-2494 [PMID: 20215504 DOI: 10.1158/0008-5472.CAN-09-3145]
64. Yotsumoto F, Fukami T, Yagi H, Funakoshi A, Yoshizato T, Kuroki M, Miyamoto S. Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci 2010; 101: 2351-2360 [PMID: 20726858 DOI: 10.1111/j.1349-7006.2010.01671.x]
65. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, von Werder A, Schmidt A, Mages J, Pagel P, Schnieke A, Schmid RM, Schneider G, Saur D. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009; 137: 361-371, 371.e1-5 [PMID: 19362090 DOI: 10.1053/j.gastro.2009.04.004]
66. Tepass U, Truong K, Godt D, Ikura M, Peifer M. Cadherins in embryonic and neural morphogenesis. Nat Rev Mol Cell Biol 2000; 1: 91-100 [PMID: 11253370 DOI: 10.1038/35040042]
67. Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 2005; 6: 622-634 [PMID: 16025097 DOI: 10.1038/nrm1699]
68. Carneiro P, Figueiredo J, Bordeira-Carric¸o R, Fernandes MS, Carvalho J, Oliveira C, Seruca R. Therapeutic targets associated to E-cadherin dysfunction in gastric cancer. Expert Opin Ther Targets 2013; 17: 1187-1201 [PMID: 23957294 DOI: 10.1517/14728222.2013.827174]
69. Qazi AM, Gruzdyn O, Semaan A, Seward S, Chamala S, Dhulipala V, Sethi S, Ali-Fehmi R, Philip PA, Bouwman DL, Weaver DW, Gruber SA, Batchu RB. Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. Surgery 2012; 152: 704-711; discussion 711-713 [PMID: 22943841 DOI: 10.1016/j.surg.2012.07.020]
70. Winter JM, Ting AH, Vilardell F, Gallmeier E, Baylin SB, Hruban RH, Kern SE, Iacobuzio-Donahue CA. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 2008; 14: 412-418 [PMID: 18223216 DOI: 10.1158/1078-0432.CCR-07-0487]
71. Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ, Hong SC, Choi SK, Ha WS, Kim JW, Lee CW, Lee JS, Park ST. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007; 120: 2331-2338 [PMID: 17304502 DOI: 10.1002/ijc.22434]
72. Horiguchi N, Arimoto K, Mizutani A, Endo-Ichikawa Y, Nakada H, Taketani S. Galectin-1 induces cell adhesion to the extracellular matrix and apoptosis of non-adherent human colon cancer Colo201 cells. J Biochem 2003; 134: 869-874 [PMID: 14769876 DOI: 10.1093/jb/mvg213]
73. Paclik D, Danese S, Berndt U, Wiedenmann B, Dignass A, Sturm A. Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLoS One 2008; 3: e2629 [PMID: 18612433 DOI: 10.1371/journal.pone.0002629]
74. Belo AI, van der Sar AM, Tefsen B, van Die I. Galectin-4 Reduces Migration and Metastasis Formation of Pancreatic Cancer Cells. PLoS One 2013; 8: e65957 [PMID: 23824659 DOI: 10.1371/journal.pone.0065957]
75. Boll M, Fuchs G, Meier C, Trautwein A, El Kasmi A, Ragsdale SW, Buchanan G, Lowe DJ. Redox centers of 4-hydroxy-benzoyl-CoA reductase, a member of the xanthine oxidase family of molybdenum-containing enzymes. J Biol Chem 2001; 276: 47853-47862 [PMID: 11602591]
76. Rumilla KM, Erickson LA, Erickson AK, Lloyd RV. Galectin-4 expression in carcinoid tumors. Endocr Pathol 2006; 17: 243-249 [PMID: 17308361]
77. Jung H, Lee KP, Park SJ, Park JH, Jang YS, Choi SY, Jung JG, Jo K, Park DY, Yoon JH, Park JH, Lim DS, Hong GR, Choi C, Park YK, Lee JW, Hong HJ, Kim S, Park YW. TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition. Oncogene 2008; 27: 2635-2647 [PMID: 17968309 DOI: 10.1038/sj.onc.1210914]
78. Dawelbait G, Winter C, Zhang Y, Pilarsky C, Grützmann R, Heinrich JC, Schroeder M. Structural templates predict novel protein interactions and targets from pancreas tumour gene expression data. Bioinformatics 2007; 23: i115-i124 [PMID: 17646287 DOI: 10.1093/bioinformatics/btm188]
79. Kim S, Kang HY, Nam EH, Choi MS, Zhao XF, Hong CS, Lee JW, Lee JH, Park YK. TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin alpha5 and its signaling pathways. Carcinogenesis 2010; 31: 597-606 [PMID: 20118200 DOI: 10.1093/carcin/bgq024]
80. Min HJ, Lee Y, Zhao XF, Park YK, Lee MK, Lee JW, Kim S. TMPRSS4 upregulates uPA gene expression through JNK signaling activation to induce cancer cell invasion. Cell Signal 2014; 26: 398-408 [PMID: 23978400 DOI: 10.1016/j.cellsig.2013.08.002]
81. Schimmer AD . Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004; 64: 7183-7190 [PMID: 15492230 DOI: 10.1158/0008-5472.CAN-04-1918]
82. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14: 5000-5005 [PMID: 18698017 DOI: 10.1158/1078-0432.CCR-08-0746]
83. Delvaeye M, De Vriese A, Zwerts F, Betz I, Moons M, Autiero M, Conway EM. Role of the 2 zebrafish survivin genes in vasculo-angiogenesis, neurogenesis, cardiogenesis and hematopoiesis. BMC Dev Biol 2009; 9: 25 [PMID: 19323830 DOI: 10.1186/1471-213X-9-25]
84. Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, Marusawa H, Zou H, Armstrong R, Matsuzawa S, Salvesen GS, Reed JC, Altieri DC. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004; 279: 34087-34090 [PMID: 15218035 DOI: 10.1074/jbc.C400236200]
85. Karikari CA, Roy I, Tryggestad E, Feldmann G, Pinilla C, Welsh K, Reed JC, Armour EP, Wong J, Herman J, Rakheja D, Maitra A. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2007; 6: 957-966 [PMID: 17339366 DOI: 10.1158/1535-7163.MCT-06-0634]
86. Zai HY, Yi XP, Li YX, You XY, Cao LP, Liu H. [X-linked inhibitor of apoptosis protein (XIAP) and Survivin suppression on human pancreatic cancer cells Panc-1 proliferation and chemosensitivety]. Beijing Daxue Xuebao 2013; 45: 242-249 [PMID: 23591345]
87. Chang TC, Mendell JT. microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet 2007; 8: 215-239 [PMID: 17506656 DOI: 10.1146/annurev. genom.8.080706.092351]
88. Tang S, Bonaroti J, Unlu S, Liang X, Tang D, Zeh HJ, Lotze MT. Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Pancreas 2013; 42: 740-759 [PMID: 23774697 DOI: 10.1097/MPA.0b013e3182854ab0]
89. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, Maitra A. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 2011; 10: 1470-1480 [PMID: 21622730 DOI: 10.1158/1535-7163.MCT-11-0152]
90. Kent OA, Mullendore M, Wentzel EA, López-Romero P, Tan AC, Alvarez H, West K, Ochs MF, Hidalgo M, Arking DE, Maitra A, Mendell JT. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 2009; 8: 2013-2024 [PMID: 20037478 DOI: 10.4161/cbt.8.21.9685]
91. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211-215 [PMID: 21240262 DOI: 10.1038/nm.2284]
92. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745-752 [PMID: 17540599 DOI: 10.1016/j.molcel.2007.05.010]
93. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, Xu L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8: 266 [PMID: 18803879 DOI: 10.1186/1471-2407-8-266]
94. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, Desano JT, Bommer GT, Fan D, Fearon ER, Lawrence TS, Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009; 4: e6816 [PMID: 19714243 DOI: 10.1371/journal.pone.0006816]
95. Hu Y, Ou Y, Wu K, Chen Y, Sun W. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumour Biol 2012; 33: 1863-1870 [PMID: 23070684 DOI: 10.1007/s13277-012-0446-8]
96. Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, Liu S, Leach SD, Maitra A, Mendell JT. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev 2010; 24: 2754-2759 [PMID: 21159816 DOI: 10.1101/gad.1950610]
97. Pham H, Rodriguez CE, Donald GW, Hertzer KM, Jung XS, Chang HH, Moro A, Reber HA, Hines OJ, Eibl G. miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells. Biochem Biophys Res Commun 2013; 439: 6-11 [PMID: 23973710 DOI: 10.1016/j.bbrc.2013.08.042]
98. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30: 377-386 [PMID: 19136477 DOI: 10.1093/carcin/bgp014]
99. Moore AE, Young LE, Dixon DA. A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts mi-croRNA-mediated regulation. Oncogene 2012; 31: 1592-1598 [PMID: 21822307 DOI: 10.1038/onc.2011.349]
100. Soubani O, Ali AS, Logna F, Ali S, Philip PA, Sarkar FH. Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Carcinogenesis 2012; 33: 1563-1571 [PMID: 22637745 DOI: 10.1093/carcin/bgs189]
101. Kim S, Huang W, Mottillo EP, Sohail A, Ham YA, Conley-Lacomb MK, Kim CJ, Tzivion G, Kim HR, Wang S, Chen YQ, Fridman R. Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP. Biochim Biophys Acta 2010; 1803: 1287-1297 [PMID: 20620173 DOI: 10.1016/j.bbamcr.2010.06.011]
102. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003; 22: 974-982 [PMID: 12592384 DOI: 10.1038/sj.onc.1206197]
103. Petrella BL, Brinckerhoff CE. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renalcell carcinoma. Cancer Biol Ther 2009; 8: 1389-1401 [PMID: 19483472 DOI: 10.4161/cbt.8.14.8880]
104. Reis EM, Verjovski-Almeida S. Perspectives of Long Non-Coding RNAs in Cancer Diagnostics. Front Genet 2012; 3: 32 [PMID: 22408643 DOI: 10.3389/fgene.2012.00032]
105. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009; 10: 155-159 [PMID: 19188922 DOI: 10.1038/nrg2521]
106. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P, Brown JB, Lipovich L, Gonzalez JM, Thomas M, Davis CA, Shiekhattar R, Gingeras TR, Hubbard TJ, Notredame C, Harrow J, Guigó R. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012; 22: 1775-1789 [PMID: 22955988 DOI: 10.1101/gr.132159.111]
107. Sana J, Faltejskova P, Svoboda M, Slaby O. Novel classes of non-coding RNAs and cancer. J Transl Med 2012; 10: 103 [PMID: 22613733 DOI: 10.1186/1479-5876-10-103]
108. Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol 2013; 45: 1895-1910 [PMID: 23748105 DOI: 10.1016/j.biocel.2013.05.030]
109. Kapranov P, St Laurent G, Raz T, Ozsolak F, Reynolds CP, Sorensen PH, Reaman G, Milos P, Arceci RJ, Thompson JF, Triche TJ. The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol 2010; 8: 149 [PMID: 21176148 DOI: 10.1186/1741-7007-8-149]
110. Tahira AC, Kubrusly MS, Faria MF, Dazzani B, Fonseca RS, Maracaja-Coutinho V, Verjovski-Almeida S, Machado MC, Reis EM. Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. Mol Cancer 2011; 10: 141 [PMID: 22078386 DOI: 10.1186/1476-4598-10-141]
111. Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, Thorne LB, Calvo BF, Kim HJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Perou CM, Yeh JJ. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med 2010; 7: e1000307 [PMID: 20644708 DOI: 10.1371/journal.pmed.1000307]
112. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, Regev A, Lander ES, Rinn JL. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 2009; 106: 11667-11672 [PMID: 19571010 DOI: 10.1073/pnas.0904715106]
113. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011; 43: 904-914 [PMID: 21925379 DOI: 10.1016/j.molcel.2011.08.018]
114. Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, Kim S, Safe S. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 2013; 32: 1616-1625 [PMID: 22614017 DOI: 10.1038/onc.2012.193]
115. Gutschner T, Hämmerle M, Diederichs S. MALAT1 - a paradigm for long noncoding RNA function in cancer. J Mol Med (Berl) 2013; 91: 791-801 [PMID: 23529762 DOI: 10.1007/s00109-013-1028-y]
116. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Müller-Tidow C. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22: 8031-8041 [PMID: 12970751 DOI: 10.1038/sj.onc.1206928]
117. Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zörnig M, MacLeod AR, Spector DL, Diederichs S. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 2013; 73: 1180-1189 [PMID: 23243023 DOI: 10.1158/0008-5472.CAN-12-2850]
118. Ji Q, Liu X, Fu X, Zhang L, Sui H, Zhou L, Sun J, Cai J, Qin J, Ren J, Li Q. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway. PLoS One 2013; 8: e78700 [PMID: 24244343 DOI: 10.1371/journal.pone.0078700]
119. Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, Zhang Y, Gorospe M, Prasanth SG, Lal A, Prasanth KV. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet 2013; 9: e1003368 [PMID: 23555285 DOI: 10.1371/journal.pgen.1003368]
120. Schneider G, Krämer OH, Fritsche P, Schüler S, Schmid RM, Saur D. Targeting histone deacetylases in pancreatic ductal adenocarcinoma. J Cell Mol Med 2010; 14: 1255-1263 [PMID: 19929947 DOI: 10.1111/j.1582-4934.2009.00974.x]
121. Ouaïssi M, Cabral S, Tavares J, da Silva AC, Mathieu Daude F, Mas E, Bernard J, Sastre B, Lombardo D, Ouaissi A. Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. Cancer Biol Ther 2008; 7: 523-531 [PMID: 18296916 DOI: 10.4161/cbt.7.4.5480]
122. Fritsche P, Seidler B, Schüler S, Schnieke A, Göttlicher M, Schmid RM, Saur D, Schneider G. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009; 58: 1399-1409 [PMID: 19528037 DOI: 10.1136/gut.2009.180711]
123. Gong DJ, Zhang JM, Yu M, Zhuang B, Guo QQ. Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma. Clin Interv Aging 2013; 8: 889-897 [PMID: 23898224 DOI: 10.2147/CIA.S45064]
124. Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, Denkert C, Imre G, Weller C, Hofmann HP, Niesporek S, Jacob J, Dietel M, Scheidereit C, Kristiansen G. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 2007; 97: 523-530 [PMID: 17622249 DOI: 10.1038/sj.bjc.6603878]
125. Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, Noske A, Müller BM, Bahra M, Neuhaus P, Dietel M, Kristiansen G, Weichert W. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009; 9: 395 [PMID: 19912635 DOI: 10.1186/1471-2407-9-395]
126. Hu J, Colburn NH. Histone deacetylase inhibition downregulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res 2005; 3: 100-109 [PMID: 15755876 DOI: 10.1158/1541-7786.MCR-04-0070]
127. Song W, Tao K, Li H, Jin C, Song Z, Li J, Shi H, Li X, Dang Z, Dou K. Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci 2010; 101: 1754-1760 [PMID: 20426791 DOI: 10.1111/j.1349-7006.2010.01577.x]
128. Yin T, Wei H, Leng Z, Yang Z, Gou S, Wu H, Zhao G, Hu X, Wang C. Bmi-1 promotes the chemoresistance, invasion and tumorigenesis of pancreatic cancer cells. Chemotherapy 2011; 57: 488-496 [PMID: 22248802 DOI: 10.1159/000334103]
129. Proctor E, Waghray M, Lee CJ, Heidt DG, Yalamanchili M, Li C, Bednar F, Simeone DM. Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PLoS One 2013; 8: e55820 [PMID: 23437065 DOI: 10.1371/journal.pone.0055820]
130. van Vlerken LE, Kiefer CM, Morehouse C, Li Y, Groves C, Wilson SD, Yao Y, Hollingsworth RE, Hurt EM. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Stem Cells Transl Med 2013; 2: 43-52 [PMID: 23283488 DOI: 10.5966/sctm.2012-0036]
131. Fujii S, Fukamachi K, Tsuda H, Ito K, Ito Y, Ochiai A. RAS oncogenic signal upregulates EZH2 in pancreatic cancer. Biochem Biophys Res Commun 2012; 417: 1074-1079 [PMID: 22222375 DOI: 10.1016/j.bbrc.2011.12.099]
132. Banerjee R, Mani RS, Russo N, Scanlon CS, Tsodikov A, Jing X, Cao Q, Palanisamy N, Metwally T, Inglehart RC, Tomlins S, Bradford C, Carey T, Wolf G, Kalyana-Sundaram S, Chinnaiyan AM, Varambally S, D'Silva NJ. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene 2011; 30: 4339-4349 [PMID: 21532618 DOI: 10.1038/onc.2011.141]
133. Li CH, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE, Chen Y. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Gastroenterology 2013; 144: 1086-1097.e9 [PMID: 23395645 DOI: 10.1053/j.gastro.2013.01.058]
134. Deng J, He M, Chen L, Chen C, Zheng J, Cai Z. The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival. PLoS One 2013; 8: e76450 [PMID: 24116110 DOI: 10.1371/journal.pone.0076450]
135. Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, Honeywell RJ, Danesi R, Peters GJ, Giovannetti E. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther 2012; 11: 1735-1746 [PMID: 22622284 DOI: 10.1158/1535-7163. MCT-12-0037]
136. Lasfargues C, Pyronnet S. EZH2 links pancreatitis to tissue regeneration and pancreatic cancer. Clin Res Hepatol Gastroenterol 2012; 36: 323-324 [PMID: 22766150 DOI: 10.1016/j.clinre.2012.05.010]
137. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17: 3112-3126 [PMID: 14681207 DOI: 10.1101/gad.1158703]
138. Pietras A . Cancer stem cells in tumor heterogeneity. Adv Cancer Res 2011; 112: 255-281 [PMID: 21925307 DOI: 10.1016/B978-0-12-387688-1.00009-0]
139. Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 2007; 1: 241-242 [PMID: 18371356 DOI: 10.1016/j.stem.2007.08.012]
140. Rasheed ZA, Kowalski J, Smith BD, Matsui W. Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells 2011; 29: 883-887 [PMID: 21509907 DOI: 10.1002/stem.648]
141. Xia J, Chen C, Chen Z, Miele L, Sarkar FH, Wang Z. Targeting pancreatic cancer stem cells for cancer therapy. Biochim Biophys Acta 2012; 1826: 385-399 [PMID: 22728049 DOI: 10.1016/j.bbcan.2012.06.002]
142. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; 425: 851-856 [PMID: 14520413 DOI: 10.1038/nature02009]
143. Singh BN, Fu J, Srivastava RK, Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One 2011; 6: e27306 [PMID: 22087285 DOI: 10.1371/journal.pone.0027306]
144. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L, Sarkar FH. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011; 307: 26-36 [PMID: 21463919 DOI: 10.1016/j.canlet.2011.03.012]
145. Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 2013; 335: 41-51 [PMID: 23402814 DOI: 10.1016/j.canlet.2013.01.054]
146. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323 [PMID: 18371365 DOI: 10.1016/j.stem.2007.06.002]
147. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009; 75: 1240-1247 [PMID: 19255243 DOI: 10.1124/mol.108.053389]
148. Bao B, Wang Z, Ali S, Kong D, Banerjee S, Ahmad A, Li Y, Azmi AS, Miele L, Sarkar FH. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem 2011; 112: 2296-2306 [PMID: 21503965 DOI: 10.1002/jcb.23150]
149. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66: 8319-8326 [PMID: 16951136 DOI: 10.1158/0008-5472.CAN-06-0410]
150. Wang Z, Ahmad A, Banerjee S, Azmi A, Kong D, Li Y, Sarkar FH. FoxM1 is a novel target of a natural agent in pancreatic cancer. Pharm Res 2010; 27: 1159-1168 [PMID: 20354770 DOI: 10.1007/s11095-010-0106-x]
151. Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol 2009; 568: 161-173 [PMID: 19582426 DOI: 10.1007/978-1-59745-280-9-10]
152. Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliano M, Simeone DM. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011; 141: 2218-2227.e5 [PMID: 21864475 DOI: 10.1053/j.gastro.2011.08.009]
153. Hage C, Rausch V, Giese N, Giese T, Schönsiegel F, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Herr I. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis 2013; 4: e627 [PMID: 23661005 DOI: 10.1038/cddis.2013.158]
154. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008; 29: 290-308 [PMID: 18619669 DOI: 10.1016/j.mam.2008.05.002]
155. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27: 5287-5297 [PMID: 19738110 DOI: 10.1200/JCO.2009.23.5556]
156. Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000; 148: 615-624 [PMID: 10662785 DOI: 10.1083/jcb.148.3.615]
157. Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 2000; 105: 143-150 [PMID: 10642592 DOI: 10.1172/JCI7091]
158. Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, de Strooper B, Hartmann D, Saftig P. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci USA 2005; 102: 9182-9187 [PMID: 15958533 DOI: 10.1073/pnas.0500918102]
159. Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998; 55: 29-42 [PMID: 9473407 DOI: 10.1006/mvre.1997.2056]
160. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454 [PMID: 12189386 DOI: 10.1038/nrc822]
161. Gaida MM, Haag N, Günther F, Tschaharganeh DF, Schirmacher P, Friess H, Giese NA, Schmidt J, Wente MN. Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int J Mol Med 2010; 26: 281-288 [PMID: 20596609 DOI: 10.3892/ijmm-00000463]
162. Krüger A, Arlt MJ, Gerg M, Kopitz C, Bernardo MM, Chang M, Mobashery S, Fridman R. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 2005; 65: 3523-3526 [PMID: 15867341 DOI: 10.1158/0008-5472.CAN-04-3570]
163. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008; 1: re6 [PMID: 18612141 DOI: 10.1126/scisignal.127re6]
164. Bogaczewicz J, Jasielski P, Mosiewicz A, Trojanowski T, Suchozebrska-Jesionek D, Stryjecka-Zimmer M. [The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in invasion of tumours of neuroepithelial tissue]. Neurol Neurochir Pol 2006; 40: 404-412 [PMID: 17103354 DOI: 10.1080/10408360801973244]
165. Won JH, Zhang Y, Ji B, Logsdon CD, Yule DI. Phenotypic changes in mouse pancreatic stellate cell Ca2+ signaling events following activation in culture and in a disease model of pancreatitis. Mol Biol Cell 2011; 22: 421-436 [PMID: 21148289 DOI: 10.1091/mbc.e10-10-0807]
166. Lonardo E, Frias-Aldeguer J, Hermann PC, Heeschen C. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle 2012; 11: 1282-1290 [PMID: 22421149 DOI: 10.4161/cc.19679]
167. Bissell DM, Friedman SL, Maher JJ, Roll FJ. Connective tissue biology and hepatic fibrosis: report of a conference. Hepatology 1990; 11: 488-498 [PMID: 2179098 DOI: 10.1002/hep.1840110322]
168. Schneider E, Schmid-Kotsas A, Zhao J, Weidenbach H, Schmid RM, Menke A, Adler G, Waltenberger J, Grünert A, Bachem MG. Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells. Am J Physiol Cell Physiol 2001; 281: C532-C543 [PMID: 11443052]
169. Pandol S, Gukovskaya A, Edderkaoui M, Dawson D, Eibl G, Lugea A. Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol 2012; 27 Suppl 2: 127-134 [PMID: 22320930 DOI: 10.1111/j.1440-1746.2011.07013.x]
170. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013; 62: 112-120 [PMID: 22466618 DOI: 10.1136/gutjnl-2012-302529]
171. Apte MV, Yang L, Phillips PA, Xu Z, Kaplan W, Cowley M, Pirola RC, Wilson JS. Extracellular matrix composition significantly influences pancreatic stellate cell gene expression pattern: role of transgelin in PSC function. Am J Physiol Gastrointest Liver Physiol 2013; 305: G408-G417 [PMID: 23868411 DOI: 10.1152/ajpgi.00016.2013]
172. Walter K, Omura N, Hong SM, Griffith M, Vincent A, Borges M, Goggins M. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin Cancer Res 2010; 16: 1781-1789 [PMID: 20215540 DOI: 10.1158/1078-0432.CCR-09-1913]
173. Hebrok M. Hedgehog signaling in pancreas development. Mech Dev 2003; 120: 45-57 [PMID: 12490295 DOI: 10.1016/S0925-4773(02)00331-3]
174. Katoh Y, Katoh M. Hedgehog signaling pathway and gastrointestinal stem cell signaling network (review). Int J Mol Med 2006; 18: 1019-1023 [PMID: 17089004]
175. Chowdhury S, Pradhan RN, Sarkar RR. Structural and logical analysis of a comprehensive hedgehog signaling pathway to identify alternative drug targets for glioma, colon and pancreatic cancer. PLoS One 2013; 8: e69132 [PMID: 23935937 DOI: 10.1371/journal.pone.0069132]
176. Rodova M, Fu J, Watkins DN, Srivastava RK, Shankar S. Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal. PLoS One 2012; 7: e46083 [PMID: 23029396 DOI: 10.1371/journal.pone.0046083]
177. Hao K, Tian XD, Qin CF, Xie XH, Yang YM. Hedgehog signaling pathway regulates human pancreatic cancer cell proliferation and metastasis. Oncol Rep 2013; 29: 1124-1132 [PMID: 23292285 DOI: 10.3892/or.2012.2210]
178. Michl P, Gress TM. Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid. Gut 2012; 61: 1377-1379 [PMID: 22661496 DOI: 10.1136/gutjnl-2012-302604]
179. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA. Stromal biology and therapy in pancreatic cancer. Gut 2011; 60: 861-868 [PMID: 20966025 DOI: 10.1136/gut.2010.226092]
180. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007; 6: 1186-1197 [PMID: 17406031 DOI: 10.1158/1535-7163.MCT-06-0686]
181. Mahlbacher V, Sewing A, Elsässer HP, Kern HF. Hyaluronan is a secretory product of human pancreatic adenocarcinoma cells. Eur J Cell Biol 1992; 58: 28-34 [PMID: 1644063]
182. Toole BP, Slomiany MG. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 2008; 18: 244-250 [PMID: 18534864 DOI: 10.1016/j.semcancer.2008.03.009]
183. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 418-429 [PMID: 22439937 DOI: 10.1016/j.ccr.2012.01.007]
184. Wang Y, Ma J, Chow SC, Li CH, Xiao Z, Feng R, Fu J, Chen Y. A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2. Tumour Biol 2014; 35: 205-212 [PMID: 23897557 DOI: 10.1007/s13277-013-1025-3]